Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejected over issues with its manufacturing and distribution.
The drug, known generically as bulevirtide, treats chronic hepatitis …
The steady stream of biotech IPOs on the Nasdaq this year has continued, with Kardigan the latest to make its intention to list known.
Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with chronic liver disease.
A $140m fund launched by philanthropic group Coefficient Giving will try to find the first vaccine for Strep A, which kills 639,000 people a year.
Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over claims it is abusing its market position regarding a
Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8bn.
Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejected over issues with its manufacturing and distribution.
The drug, known generically as bulevirtide, treats chronic hepatitis …